Insulin-like growth factor I (IGF-I) is a potent mitogen for both normal and transformed mammary epithelial cells (MEC), and IGFbinding protein-3 (IGFBP-3) potentiates IGF-I action in these cells. The synthesis of IGFBP-3 is stimulated by both IGF-I and agents that increase intracellular cAMP (e.g. forskolin) in the bovine MEC line MAC-T. In addition, the combination of IGF-I and cAMP increases IGFBP-3 messenger RNA to a greater extent than does either treatment alone. The molecular mechanisms responsible for this regulation are not known and therefore represent the focus of this study. The half-life of IGFBP-3 messenger RNA in untreated MAC-T cells was determined to be 11 h. Exposure to IGF-I or forskolin increased the half-life to 27 and 101 h, respectively. Nuclear run-on assays indicated that IGFBP-3 transcription rates were increased 3.5 Ϯ 0.83-fold (n ϭ 4) in cells treated with a combination of IGF-I and forskolin. To further study this regulation, 1
IGF-I and forskolin alone produced small, but significant, increases in IGFBP-3 promoter activity of 1.57 Ϯ 0.12 and 1.59 Ϯ 0.08-fold (P Ͻ 0.01), respectively (mean Ϯ SE; n ϭ 7). However, the combination of IGF-I and forskolin increased IGFBP-3 promoter activity 2.25 Ϯ 0.14-fold above control values (P Ͻ 0.01), suggesting that these factors activate discrete signaling pathways that act in concert to stimulate IGFBP-3 gene transcription. Deletion analysis indicated that promoter fragments containing as little as 267 bp upstream of the TATA box retained responsiveness to IGF-I and forskolin. This region contains a 200-bp sequence that is approximately 80% homologous between the murine and bovine promoters. It contains several conserved AP-2 and Sp1 consensus binding sequences that may be important for the effects of IGF-I and forskolin on IGFBP-3 promoter activity. In summary, these data indicate that IGF-I and cAMP, working through separate signaling pathways, activate both transcriptional and posttranscriptional mechanisms to stimulate IGFBP-3 synthesis in MEC. T HE INSULIN-LIKE growth factors (IGF-I and -II) are key regulators of cellular proliferation, differentiation, and apoptosis (1) . All three processes are critical to the successive rounds of growth, development, and involution that the mammary gland undergoes during postnatal life. A role for IGF-I as a mitogen for normal mammary epithelial cells (MEC) as well as breast tumor cell lines has been clearly established in vitro (2) . IGF-I has been shown to promote ductal elongation and to stimulate alveolar bud development in whole organ mammary cultures (3, 4) . In vivo, intramammary administration of IGF-I stimulates terminal end bud formation and alveolar development in rats (5, 6) . Transgenic models have demonstrated that mammary-specific expression of IGF-I during early puberty promotes branching morphogenesis and alveolar development in mice (7) . Collectively, these studies show that IGF-I stimulates MEC growth. In addition, unequivocal evidence that IGF-I is essential for normal mammary gland development has recently been provided by genetic ablation studies. Mammary ductal elongation and branching morphogenesis were impaired in female IGF-I knockout mice (8) . Treatment with des-IGF-I restored terminal end bud formation after 3 days of treatment, with substantial ductal elongation occurring after 14 days of treatment.
The biological activity of the IGFs is regulated by a family of high affinity binding proteins (IGFBP-1 through -6) with which they associate. IGFBP-3 has been shown to potentiate IGF-stimulated DNA synthesis in both bovine MEC (9) and breast tumor cells (10) . In addition, transgenic mice with IGFBP-3 expression targeted to the mammary gland during late pregnancy exhibited a decrease in mammary involution after cessation of lactation (11) . In contrast, IGFBP-3 has been shown to inhibit cellular growth and/or promote apoptosis in breast tumor cell lines via IGF-independent mechanisms (12, 13) . The ability of various antiproliferative agents to inhibit cellular growth has been shown to be mediated via IGFBP-3 (13) (14) (15) . These studies suggest that IGFBP-3 may differentially regulate MEC growth depending on the pres-ence of other regulatory factors present in the extracellular environment.
Although several hormones, growth factors, and intracellular signaling agents have been shown to regulate IGFBP-3 synthesis in different cell types, little is known concerning the molecular mechanisms by which this occurs. We have shown that IGF-I specifically stimulates the synthesis of IGFBP-3 by the bovine MEC line MAC-T via an IGF-I receptor-dependent mechanism (16) . A second factor that stimulates IGFBP-3 synthesis in these cells is cAMP. The combination of these two treatments induces greater increases in IGFBP-3 protein and messenger RNA (mRNA) levels than does either treatment alone. The goal of the present study was to delineate the molecular mechanisms by which IGF-I and cAMP regulate IGFBP-3 synthesis in bovine MEC. (17) were routinely grown in DMEM supplemented with 4.5 g/liter glucose, 10% FBS, 4 mm glutamine, gentamicin (50 g/ml), penicillin (100 U/ml), and streptomycin (20 g/ml). The bovine fibroblast cell line AG08130 was obtained from the Coriell Institute for Medical Research (Camden, NJ) and grown in medium similar to that used for MAC-T cells, except that 20% FBS was used. To study the regulation of IGFBP-3 mRNA levels, cells were plated at 1.0 ϫ 10 4 cells/cm 2 on 50-mm dishes, grown to confluence, rinsed twice with serum-free DMEM, then incubated in serum-free DMEM at 37 C for various times depending on the experiment. After the washout period, media were aspirated, and treatments were added in serum-free medium. For studies of mRNA stability, cells were plated, grown to confluence, and rinsed twice in serum-free DMEM. After a 2-h washout period, cells were preincubated with the appropriate treatments for 3 h at 37 C, then DRB was added to the cultures at a final concentration of 75 m. Cells were then incubated for varying lengths of time before RNA isolation.
Materials and Methods

Reagents and general methods
Cell culture and treatments
MAC-T bovine MEC
RNA analysis
Total RNA was extracted using Tri-Reagent (Molecular Research Center, Inc., Cincinnati, OH) according to the manufacturer's recommendations. RNA concentrations and integrity were determined by absorbance at 260 and 280 nm. After denaturation with 2.2 m formaldehyde and 12.5 m formamide at 55 C for 15 min, RNA was separated by electrophoresis on a 1.0% agarose gel containing 2.2 m formaldehyde and transferred to nylon membranes (Biotrans, ICN Biomedicals, Inc., Irving, CA). The membranes were hybridized overnight at 65 C with [ 32 P]deoxy-CTP-labeled bovine IGFBP-3, bovine IGFBP-2, and 18S ribosomal complementary DNA (cDNA) probes (16) in 0.25 m sodium phosphate, 7% SDS, and 1 mm EDTA, pH 7.2. Membranes were washed twice in 2 ϫ SSC (standard saline citrate) plus 0.1% SDS and twice in 0.1 ϫ SSC plus 0.1% SDS at 65 C for 20 min/wash. Membranes were exposed to Kodak AR film (Eastman Kodak Co., Rochester, NY) with intensifying screens at Ϫ80 C. Differences in relative band intensities were determined using a PhosphorImager (Molecular Dynamics, Inc., Sunnyvale CA).
Nuclear run-on analysis
MAC-T cells were plated on 100-mm plates and grown to confluence as described above. After a 16-h incubation in serum-free medium, cells were exposed to serum-free media with or without treatments for 2 h. Relative transcription rates were determined by a previously reported method (18) . Cells were rinsed twice with ice-cold PBS, removed by scraping, and centrifuged at 500 ϫ g. The cell pellets were resuspended in ice-cold lysis buffer [10 mm Tris-Cl (pH 7.4), 3 mm CaCl 2 , and 2 mm MgCl 2 ], centrifuged, and resuspended in lysis buffer containing 0.5% Nonidet P-40. Cells were lysed with a Dounce homogenizer (Kontes Co., Vineland, NJ), and nuclei were collected by centrifugation at 500 ϫ g. The nuclei were resuspended in 200 l 50 mm Tris-Cl (pH 8.3), 40% glycerol, 5 mm MgCl 2 , and 0.1 mm EDTA and stored in liquid nitrogen until the run-on assay was performed. Thawed nuclei were incubated with 1 mm each of ATP, CTP, and GTP; 100 Ci ␣- 32 P-Labeled RNA transcripts were phenolchloroform extracted and purified using a Quick-Spin high capacity column (Roche, Indianapolis, MN). RNA was precipitated and resuspended in 10 mm N-Tris (hydrozymethyl) methyl-2-aminoethanesulfonic acid (pH 7.4), 10 mm EDTA, and 0.2% SDS (TES solution). Fifteen micrograms of plasmid DNA containing IGFBP-3 or IGFBP-2 insert or vector DNA alone were linearized, denatured with NaOH, and immobilized on nylon membrane (Bio-Rad Laboratories, Inc., Hercules, CA) with a slot blotter. The membranes were prehybridized in 0.25 m sodium phosphate, 7% SDS, and 1 mm EDTA, pH 7.2. Labeled transcripts (5 ϫ 10 6 cpm) were hybridized with each membrane in TES solution containing 300 mm NaCl for 60 h at 55 C. The membranes were washed four times in 2 ϫ SSC containing 0.1% SDS for 30 min, then incubated for 30 min at 37 C with 10 g/ml RNase A in 2 ϫ SSC before a final wash in 2 ϫ SSC at 37 C for 1 h. Membranes were exposed to Kodak AR film with intensifying screens at Ϫ80 C. Differences in relative band intensities were determined using a PhosphorImager (Molecular Dynamics, Inc.).
Cloning of the 5Ј-flanking region of the murine IGFBP-3 gene and plasmid construction
A cDNA corresponding to exons 2-4 of the rat IGFBP-3 gene (19) was used to screen a mouse genomic library (129SvJ in Fix II (Stratagene, La Jolla, CA). One of the isolated clones was shown by Southern analysis and sequencing to contain the entire coding region of the mouse IGFBP-3 gene (20) , the 5Ј-untranslated region, and approximately 1.1 kb of 5Ј-flanking sequence. The region corresponding to nucleotides Ϫ1280 to Ϫ3 (ATG, ϩ1) was excised using the restriction endonucleases NotI and NarI and inserted by blunt end ligation into the SmaI site of the promoterless vector pGL3-Basic (Promega Corp.) in both the sense and antisense orientations.
Generation of IGFBP-3 deletion constructs
Murine IGFBP-3 promoter fragments with 5Ј-ends at nucleotides Ϫ1098, Ϫ916, Ϫ691, and Ϫ416 and a common 3Ј-end at nucleotide Ϫ3 were generated by PCR amplification using the 1.3-kb IGFBP3/pGL3 construct as template. Amplification was carried out in a DNA thermal cycler (Perkin-Elmer Corp.) using an initial denaturation at 94 C for 5 min, followed by 30 cycles of denaturation at 94 C for 1 min, annealing at 55 C for 1 min, and extension at 72 C for 1 min. A 7-min incubation at 72 C was performed at the completion of the final cycle. The sense and antisense primers incorporated unique KpnI and HindIII restriction sites, respectively, for subcloning into pGL3-Basic. Each construct was verified by sequencing in both directions.
Transfection assays
MAC-T cells were plated at 2 ϫ 10 4 cells/cm 2 in six-well plates and grown to 85% confluence. Media were aspirated, and cells were cotransfected using 5 l Cytofectene transfection reagent (Bio-Rad Laboratories, Inc.) with plasmid constructs IGFBP3/pGL3 (1.5 g) and a vector containing the Renilla luciferase gene under control of the simian virus 40 promoter to normalize for transfection efficiency (50 ng pRL-SV40, Promega Corp.). After a 5-h incubation at 37 C, medium was aspirated and replaced with complete fresh medium. After 16 h, the cells were rinsed twice in serum-free medium and incubated in serum-free medium with or without treatment. Preliminary experiments indicated that basal promoter activity decreased from 8 -24 h, whereas promoter activity remained relatively constant after exposure to IGF-I and forskolin over this interval (data not shown). Therefore, cells were treated for 24 h in all experiments. Cells were lysed in 250 l lysis buffer (Promega Corp.). The activities of firefly and Renilla luciferase were measured sequentially from individual samples using the dual luciferase reporter assay (Promega Corp.).
Statistical analysis
Differences between serum-free controls and treated groups were compared using Student's t test. P Ͻ 0.05 was considered significant.
Results
Time course of IGFBP-3 mRNA induction by IGF-I and forskolin in MAC-T cells
We have previously shown that IGF-I and forskolin increase IGFBP-3 mRNA and protein levels in MAC-T cells (16) . In addition, exposure of MAC-T cells to a combination of IGF-I and forskolin increased IGFBP-3 synthesis to a greater extent than either treatment alone. To further analyze the mechanisms by which these factors regulate IGFBP-3 synthesis, we first determined whether the induction of IGFBP-3 mRNA levels by forskolin or IGF-I plus forskolin followed a time course similar to that of IGF-I (Fig. 1) . In agreement with previous results, treatment with IGF-I increased IGFBP-3 mRNA by 3 h, with maximum increases observed between 8 -12 h of treatment. A similar time course of IGFBP-3 mRNA induction was observed with both forskolin and forskolin plus IGF-I. Treatment with either forskolin or IGF-I alone maximally increased IGFBP-3 mRNA levels 8-to 15-fold relative to those in serum-free controls. The increase in IGFBP-3 mRNA observed at each time point after treatment with both IGF-I and forskolin was always at least as great as the sum of the increases observed with each treatment alone. As IGF-I and forskolin were each tested at concentrations that maximally induce IGFBP-3 mRNA levels, the enhanced response observed with the combination suggests that these two factors activate separate signaling pathways. Neither of these treatments affected IGFBP-2 mRNA levels in MAC-T cells (16); therefore IGFBP-2 was used as a control to illustrate the specificity of the IGFBP-3 response. IGFBP-2 mRNA actually decreased over the 24-h time course examined, regardless of treatment (Fig. 1) . 
Regulation of IGFBP-3 mRNA by IGF-I and forskolin in bovine fibroblasts
The ability of IGF-I and forskolin to increase IGFBP-3 mRNA levels in bovine fibroblasts was examined to determine whether the effects observed in MAC-T cells were specific to epithelial cells (Fig. 2) . When fibroblasts were incubated with IGF-I for 8 h, IGFBP-3 mRNA levels were increased 3.3 Ϯ 0.7-fold above serum-free control values (mean Ϯ se; n ϭ 3). In contrast, treatment with forskolin failed to stimulate IGFBP-3 mRNA levels. The increase in IGFBP-3 mRNA levels observed after exposure to IGF-I and forskolin tended to be less than the increase observed with IGF-I alone. Therefore, although IGF-I increases IGFBP-3 mRNA levels in both cell types, the ability of forskolin to stimulate IGFBP-3 mRNA is specific to the mammary epithelial cell.
Effect of IGF-I and forskolin on IGFBP-3 mRNA stability
To determine whether the increase in steady state levels of IGFBP-3 mRNA seen with IGF-I or forskolin treatment in MAC-T cells was due to posttranscriptional mechanisms, the stability of IGFBP-3 mRNA transcripts was examined using DRB, a selective inhibitor of RNA polymerase II. Cultures were pretreated with IGF-I or forskolin for 3 h, followed by DRB addition to arrest gene transcription. As shown in Fig.  3 , the half-life of IGFBP-3 mRNA levels in untreated cells was approximately 11 h. Treatment with either IGF-I or forskolin enhanced the stability of IGFBP-3 mRNA. The half-life of IGFBP-3 mRNA in cells treated with IGF-I was increased to 27 h, representing a 2.4-fold increase in mRNA stability. The effect of forskolin on IGFBP-3 mRNA stability was greater than that of IGF-I, extending the half-life to 106 h. The halflife of IGFBP-3 mRNA stability in cells treated with a combination of IGF-I and forskolin was similar to that observed for forskolin alone (data not shown). This would be expected given that with forskolin alone virtually no degradation had occurred by 18 h.
Transcriptional regulation of IGFBP-3 by IGF-I and forskolin
In other cell types, increases in steady state levels of IGFBP-3 mRNA involve both transcriptional and posttranscriptional mechanisms. Therefore, the effect of IGF-I or forskolin on gene transcription was also examined using nuclear run-on assays. Treatment with either IGF-I or forskolin alone had no detectable effect on the rate of elongation of preinitiated IGFBP-3 gene transcripts in MAC-T cells (Fig. 4) . However, when cells were exposed to forskolin and IGF-I in combination, IGFBP-3 transcription rates were increased 3.5 Ϯ 0.83-fold (mean Ϯ se; n ϭ 4; P Ͻ 0.05) over IGFBP-3 transcription rates in control cells. The transcription rates of IGFBP-2 in IGF-I-and forskolin-treated cells served as negative controls, as IGF-I and forskolin do not increase IGFBP-2 mRNA levels (16) . The transcription rate of IGFBP-2 was not affected by any of the treatments.
Regulation of IGFBP-3 promoter activity by IGF-I and forskolin
To begin to identify the regions of the IGFBP-3 promoter that are responsible for the regulation by IGF-I and forskolin, MAC-T cells were transiently transfected with luciferase constructs driven by the sense or antisense promoter fragment corresponding to nucleotides Ϫ1283 to Ϫ3 of the murine gene. The murine promoter was faithfully trans-activated in these cells, as shown by the 70-fold higher luciferase activity of the sense construct relative to the antisense construct or to pGL3-Basic (Fig. 5) . Exposure of MAC-T cells to IGF-I or forskolin alone consistently produced small, but significant, increases in the activity of the sense construct of 1.57 Ϯ 0.12-and 1.59 Ϯ 0.08-fold ( Fig. 6 ; mean Ϯ se of seven experiments; P Ͻ 0.01). Treatment with both IGF-I plus forskolin produced additive increases in promoter activity in every experiment, significantly increasing luciferase activity 2.25 Ϯ 0.14% above the control value (mean Ϯ se of seven experiments; P Ͻ 0.01). Similar increases were observed when (Bu) 2 cAMP was used in place of forskolin, either alone or in combination with IGF-I (data not shown).
Preliminary experiments performed to optimize the length of treatment indicated that basal promoter activity declines between 8 -24 h of treatment (data not shown). This is in agreement with our unreported findings that serum specifically regulates IGFBP-3 mRNA levels. As both the transfections and the overnight recovery are performed in serumcontaining medium, basal promoter activity may be relatively high in the promoter assays, which could explain the smaller response to IGF-I and forskolin observed in this type of assay relative to that in the nuclear run-on assays.
Identification of regions required for regulation of IGFBP-3 promoter activity by IGF-I and forskolin
To identify the regions of the IGFBP-3 promoter mediating the effects of IGF-I and forskolin, MAC-T cells were transfected with 5Ј-deletion mutants of the IGFBP-3 promoter. As shown in Fig. 7 , deletion of the region between nucleotides Ϫ1283 and Ϫ416 of the IGFBP-3 promoter did not eliminate the ability of IGF-I and forskolin to increase luciferase activity. Comparison of the bovine and murine IGFBP-3 promoters revealed a highly conserved region in the remaining sequence that includes the TATA box and several conserved AP-2 and Sp1 binding sites (Fig. 8) . One or more of these binding sites may be involved in either basal regulation of the IGFBP-3 gene and/or regulation by IGF-I and cAMP. Studies are presently underway to identify the molecular mechanisms responsible for this regulation.
Discussion
IGFBP-3 is emerging as a multifunctional protein. It has been shown to inhibit as well as to enhance cell growth through both IGF-dependent as well as IGF-independent mechanisms (21) . The action of IGFBP-3 may be influenced by the presence of IGF in the system. In the immortalized bovine MEC line MAC-T, IGF-I specifically induces the synthesis of IGFBP-3, which then acts to potentiate the ability of IGF-I to stimulate DNA synthesis (9) . Therefore, in the presence of IGF, IGFBP-3 is a potent enhancer of DNA synthesis in these cells. The goal of the present study was to determine whether transcriptional or posttranscriptional mechanisms are responsible for the increase in IGFBP-3 synthesis observed in MAC-T cells after treatment with either IGF-I or agents such as forskolin, which elevate intracellular cAMP levels. Determining the molecular mechanisms that regulate IGFBP-3 synthesis will help to unravel the complex physiological roles of IGFBP-3.
Experiments using the transcriptional inhibitor DRB indicated that the degradation rate of IGFBP-3 mRNA in untreated MAC-T cells was approximately 11 h. IGFBP-3 mRNA degradation rates have been estimated at 14 -18 h in human hepatocarcinoma (22) or normal rat liver cells (23), 6 h in bovine kidney epithelial cells (24) , and as short as 2 h in rat Leydig cells (25) . This suggests that different mechanisms may regulate IGFBP-3 degradation depending on the cell type. A number of labile mammalian mRNAs, such as c-fos, contain AU-rich elements (ARE) in their 3Ј-untranslated regions (UTR) that have been linked to mRNA destabilization (26) . The 3Ј-UTR of the bovine IGFBP-3 mRNA is uridine rich and contains an ARE consisting of an AUUUA pentamer motif that is conserved in the human and the rat (24) . Recently, it has been shown that this region binds a 42-kDa protein present in cytoplasmic extracts of MDBK cells. This protein may belong to a family of binding proteins that bind to AREs and regulate mRNA stability (27) . However, it was shown that the AUUUA motif was not required for this protein to bind to IGFBP-3 mRNA. In contrast, two uridine stretches were shown to be critical for the RNA-protein interaction (24) . The lack of a requirement for the AUUUA motif agrees with studies using the stabile ␤-globin mRNA in which various mutant c-fos and synthetic ARE were inserted within its 3Ј-UTR. The nonamer UUAUUUAUU was found to be effective in promoting mRNA degradation, whereas the pentamer AUUUA had no effect (27) .
In the present study both IGF-I and forskolin increased the stability of IGFBP-3 mRNA. The half-life of IGFBP-3 mRNA was estimated to be 27 h in IGF-I-treated cells and 101 h in forskolin-treated cells. The effect of forskolin on IGFBP-3 turnover was more pronounced than that of IGF-I, suggesting that these factors may act to stabilize IGFBP-3 message through different mechanisms. A similar effect of IGF-I on mRNA stability has been reported with cocultures of rat liver cells (23) . In contrast, no effect of IGF-I on mRNA stability was observed with bovine endothelial cells (28) or human hepatocarcinoma cells (22) . However, in the later study where no effect was observed, the cells were not preincubated with IGF-I before DRB treatment. We found that DRB blocks the ability of IGF-I to stabilize IGFBP-3 message levels in the absence of a preincubation period with IGF-I. Thus, when added simultaneously, DRB may block the ability of IGF-I to induce the synthesis of proteins involved in stabilizing IGFBP-3 mRNA. The mechanism by which IGF-I enhances IGFBP-3 mRNA stability has not been determined for any cell type.
Forskolin has been shown to increase steady state levels of IGFBP-3 mRNA in MAC-T cells (16) , MDBK cells (24, 29) , and the human breast carcinoma cell line MCF-7 (30) . This effect may be specific for epithelial cells, as in the present study forskolin did not stimulate IGFBP-3 mRNA in bovine fibroblasts. Forskolin has been shown to stabilize IGFBP-3 mRNA levels in MDBK cells by decreasing the binding of the 42-kDa RNA-binding protein described above to the 3Ј-UTR of IGFBP-3 mRNA. This effect was shown to involve phosphorylation of the RNA binding protein via a protein kinase A-dependent mechanism (24) . Whether a similar mechanism is responsible for the increase in IGFBP-3 mRNA observed in forskolin-treated MAC-T cells is unknown.
The large increase in mRNA stability induced by forskolin appeared sufficient to account for the large increases in steady state mRNA levels observed after this treatment. In contrast, the 2.4-fold increase in stability induced by IGF-I appeared less likely to fully account for the large increases in steady state mRNA levels observed after IGF treatment. Therefore, we conducted nuclear run-on assays to investigate potential regulation by transcriptional mechanisms. The results of these assays indicated that treatment of MAC-T cells for 2 h with either forskolin or IGF-I alone had no detectable effect on the rate of IGFBP-3 transcription. In contrast, stimulation of MAC-T cells transiently transfected with the 5Ј- flanking region of the murine IGFBP-3 promoter to drive luciferase expression resulted in small, but significant, increases in luciferase activity of approximately 50%. These increases were most likely too small to detect by nuclear runon assay, which is inherently less sensitive. Overall, the relatively small increase in promoter activity of at least 1.5-fold after 24 h of IGF-I treatment together with the 2.4-fold increase in stability appeared sufficient to account for the 5-fold increase in mRNA observed after 24 h of treatment.
The time course of IGFBP-3 mRNA induction shown in Fig. 1 shows clearly that a much greater increase in mRNA is obtained when the two treatments are added together. This can only be achieved by an increase in transcription, because the combination of forskolin and IGF-I did not result in a longer half-life for IGFBP-3 mRNA than did forskolin alone. The increase in promoter activity obtained using the mouse IGFBP-3 promoter agreed well with the increase in transcription rate observed with nuclear run-on in cells treated with both IGF-I and forskolin. Similar to the results of the nuclear run-on assay, the effects of IGF-I and forskolin on promoter activity were additive when cells were treated with a combination of IGF-I plus forskolin. Therefore, the enhanced transcriptional response to IGF-I plus forskolin explains the greater response of IGFBP-3 mRNA observed with the combination of treatments.
The finding that IGF-I and forskolin together induce greater increases in IGFBP-3 promoter activity than either factor does alone indicates that these two factors activate separate signaling pathways that somehow act in concert to activate IGFBP-3 gene transcription. Support for the involvement of discrete intracellular signaling pathways comes from our observations that IGF-I does not increase intracellular cAMP levels in this cell line (our unpublished data). Although we have not examined whether cAMP increases IGF-I synthesis in MAC-T cells, the similar time frame of IGFBP-3 mRNA induction observed with either IGF-I or forskolin treatment suggests that cAMP does not increase IGFBP-3 synthesis via IGF-I. IGF-I mediates its intracellular effects via the IGF tyrosine kinase receptor (31) . In contrast, cAMP is generally increased in response to activation of membrane-associated, trimeric, G protein-coupled receptors (32) . Recently, elevations in intracellular cAMP have been shown to potentiate the ability of epidermal growth factor to activate mitogen-activated protein kinase in LNCaP prostate carcinoma cells (33) . These studies raise the possibility that cross-talk between the signaling pathways activated by cAMP and the IGF tyrosine kinase receptor may be responsible for the increase in transcriptional activation of the IGFBP-3 gene.
To identify the region containing the DNA-binding sites required for the responsiveness to IGF-I and forskolin, sequential deletion fragments of the 1.3-kb IGFBP3/pGL-3 promoter construct were generated by PCR and used in luciferase reporter assays. Promoter activity was increased to a similar extent with each deletion fragment, including the smallest fragment, which contained approximately 300 bp of 5Ј-flanking region. Similarly, using bovine IGFBP-3 deletion fragments, Erondu et al. (34) reported that a fragment containing only 128 bp upstream of the transcription start site was responsive to IGF-I in bovine endothelial cells.
The consensus binding sequences in the IGFBP-3 gene that are required for either basal responsiveness or stimulation by IGF-I/cAMP are unknown. Examination of published IGFBP-3 promoter sequences indicates that multiple DNAbinding sites for known transcription factors are present in the sequences of the human (35) , rat (36) , and bovine (34) genes. However, no studies have reported whether any of these sites are functional in terms of regulating either basal or hormonal responsiveness of the IGFBP-3 promoter. We have sequenced approximately 1 kb of the upstream 5Ј-flanking region of the murine IGFBP-3 gene and compared it with the bovine promoter sequence. Although both promoters contain a high number of consensus binding sequences for known transcription factors, the majority of these are not conserved between the two species. In contrast, the 200-bp region immediately upstream of the transcription start site exhibits 80% homology between the two species. This region contains several AP-2 and Sp1 binding sites that are conserved between the two genes. Especially interesting is the region between nucleotides Ϫ189 and Ϫ207 in the mouse and between Ϫ216 and Ϫ234 in the bovine that contains three overlapping AP-2 binding sites and two Sp1 sites. The sequence corresponding to the 3Ј-most AP-2 site in this region also represents a perfectly conserved AP-2 site in the human and rat genes. The middle site in this region is a perfect AP-2 site in the bovine and is missing one nucleotide for a perfect AP-2 consensus sequence in the rat (similar to that in the mouse).
The transcription factor AP-2 is activated by several different signaling cascades, including the cAMP-dependent protein kinase A pathway (37, 38) . This protein binds to GC-rich regions in a variety of promoters, and considerable variation has been found between individual binding sequences (38, 39) . AP-2 has also been shown to regulate basal activity of the human IGFBP-5 gene, which, like IGFBP-3, is responsive to cAMP and IGF-I (40). IGF-I regulates expression of the chicken ␦1-crystallin gene and the rat elastin gene through GC-rich sequences that bind Sp1or Sp1-like proteins (41, 42) . Therefore, these consensus binding sequences are likely to be involved in regulation of the IGFBP-3 promoter. Studies to further define the regulatory elements involved in regulation of the IGFBP-3 promoter are currently in progress.
